Confo Therapeutics announced that it has entered into a research collaboration with AbCellera for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. Confo will apply its proprietary ConfoBody technology to stabilize the selected GPCRs in their disease-relevant conformations, which will then be used as antigens to enable antibody discovery and development. Confo will be entitled to upfront payments, milestones, and tiered royalties on net product sales.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.815 USD | +2.01% | +0.52% | -32.75% |
05-07 | Transcript : AbCellera Biologics Inc., Q1 2024 Earnings Call, May 07, 2024 | |
05-07 | AbCellera Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.75% | 1.1B | |
+42.52% | 54.04B | |
+43.57% | 41.96B | |
-1.29% | 41.92B | |
-7.59% | 28.35B | |
+11.69% | 26.35B | |
-22.32% | 19B | |
+7.89% | 13B | |
+28.84% | 12.28B | |
+25.59% | 12.19B |
- Stock Market
- Equities
- ABCL Stock
- News AbCellera Biologics Inc.
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera